newsfilter
← Latest News
Business Wire·

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter